
    
      This is a Phase 4, 48-week, randomized, open-label, multicenter clinical study comprised of 2
      periods: a 24-week Dose Titration Period, followed by a 24-week Dose Maintenance Period. The
      study will consist of 12 scheduled clinic visits over a period of 48 weeks and additional
      visits as needed.
    
  